As of January 2026, the biopharmaceutical industry has moved beyond traditional "batch-and-test" methodologies to a model of continuous, data-driven assurance. According to recent Peptide Market analysis, the sector’s valuation of $65.08 billion is being sustained by a massive technological leap: the integration of Digital Twins in GxP (Good Practice) manufacturing. These digital replicas...